Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
7.44
+0.40 (5.68%)
Oct 31, 2025, 4:00 PM EST - Market closed
DAWN Revenue
Day One Biopharmaceuticals had revenue of $33.91M in the quarter ending June 30, 2025, with 313.92% growth. This brings the company's revenue in the last twelve months to $187.64M, up 2,190.50% year-over-year. In the year 2024, Day One Biopharmaceuticals had annual revenue of $131.16M.
Revenue (ttm)
$187.64M
Revenue Growth
+2,190.50%
P/S Ratio
4.01
Revenue / Employee
$1,036,674
Employees
181
Market Cap
762.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 131.16M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
DAWN News
- 12 days ago - Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 - GlobeNewsWire
- 3 months ago - Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade) - Seeking Alpha
- 3 months ago - Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Day One Reports Second Quarter 2025 Financial Results and Corporate Progress - GlobeNewsWire
- 3 months ago - Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 - GlobeNewsWire
- 5 months ago - Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development - GlobeNewsWire
- 5 months ago - Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
- 6 months ago - Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript - Seeking Alpha